3rd Line and beyond

3rd Line and beyond

If you have been NEWLY DIAGNOSED  START HERE 

Video Library

Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.
Cancer Journey:
Cancer Type:
Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.
Cancer Journey:
Cancer Type:
Dr. Greg Riely from Memorial Sloan-Kettering Cancer Center reviews the limited data that help clarify the probability of benefit from new immunotherapy agents among patients with advanced NSCLC and an identified driver mutation.
Cancer Journey:
Cancer Type:

Articles

I just did a brief video that appears on my The Swedish hospital website/blog, addressing the question of why it is standard to give single agent but...
Cancer Journey:
Cancer Type:
One of the current controversies in the field of lung cancer is whether we should be doing biopsies routinely when a patient develops progression of...
Cancer Journey:
Cancer Type:
It has been a long time since we've talked about Nexavar (sorafenib), an oral anti-angiogenic targeted therapy that works as a "multi-kinase...
Cancer Journey:
Cancer Type:
Continuing with our post-ASCO highlights presentation, we now turn to Dr. Joel Neal, Assistant Professor at Stanford Cancer Center, who covered...
Cancer Journey:
Cancer Type:
In my last post, I described the concept of treating with a targeted therapy like an EGFR tyrosine kinase inhibitor (TKI) or ALK inhibitor at the...
Cancer Journey:
Cancer Type:

Community Forum

No Result Found